|Print This Page Email to a Friend|
|Dr. Oleg Tcheremissine|
More than five million Americans live with Alzheimer's disease (AD), a figure that is expected to nearly triple over the next generation as the current population lives longer. AD is a fatal neurodegenerative disease that includes memory loss, behavior changes and loss of independence. It also places a big burden on families and other caregivers of the individual diagnosed with the disease.
There have been a number of clinical trials to test the effectiveness of drugs to help patients with AD, and while not all have been successful, the hope to find a drug that improves conditions for these patients’ lives on.
Oleg Tcheremissine, MD, research director at Carolinas Medical Center-Randolph, is participating in a trial for a drug to help patients with AD. Dr. Tcheremissine, along with researchers from CMC- Randolph and Carolinas HealthCare System’s Neurosciences Institute, is currently conducting a Phase 3, placebo controlled study in mild AD patients ages 55 to 90 years old.
The amyloid-β (Aβ) hypothesis for AD, which states that the production and deposition of Aβ is an early and necessary event in the pathogenesis of AD, suggests that treatments that slow the synthesis or deposition of Aβ, or that increase clearance, might be expected to slow the progression of AD.
The primary objective of this study is to test the hypothesis that a drug, administered as an intravenous infusion at a dose of 400 mg every four weeks for 76 weeks, will slow the cognitive decline of AD in patients with mild AD. This study is designed to collect data on the long-term safety and efficacy of the drug, including cognitive outcomes, as well as functional outcomes, quality of life, resource utilization and biomarker measures.
For additional information, please contact Dineen Gardner 704-446-7511 or Megan R. Kramer, RN 704-446-0803.